Clinical usefulness of chemosensitivity test for advanced colorectal cancer

Yasuo Kabeshima, Tetsuro Kubota, Masahiko Watanabe, Hirotoshi Hasegawa, Toshiharu Furukawa, Masaki Kitajima

研究成果: Article

7 引用 (Scopus)

抜粋

We assessed the usefulness of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay in the evaluation of appropriate adjuvant cancer chemotherapy for patients with advanced colorectal cancer. We analyzed 405 cases of colorectal cancer treated between January 1990 and August 1999 in terms of the MTT assay and survival outcome. Patients with Dukes' C and D were classified into a "surgery alone" group (n=53), a "sensitive" group who received drugs that had a greater than 50% inhibition rate by MTT assay (n=23), or "resistant"" group who were insensitive to the chemotherapy drugs (n=124). Statistically significant differences in survival outcome were observed between the groups, with the sensitive group showing significantly better survival compared with the resistant group (p=0.0158) and the surgery-alone group (p=0.0004). Our results suggest that the MTT assay may be useful in evaluating the optimum adjuvant chemotherapy for patients with advanced colorectal cancer.

元の言語English
ページ(範囲)3033-3037
ページ数5
ジャーナルAnticancer research
22
発行部数5
出版物ステータスPublished - 2002 9 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

フィンガープリント Clinical usefulness of chemosensitivity test for advanced colorectal cancer' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Kabeshima, Y., Kubota, T., Watanabe, M., Hasegawa, H., Furukawa, T., & Kitajima, M. (2002). Clinical usefulness of chemosensitivity test for advanced colorectal cancer. Anticancer research, 22(5), 3033-3037.